evidence exists to support initiation of hepatitis C virus treatment in patients with limited life expectancy (less than 12 months) due to comorbid conditions. For these patients, the benefits of hepatitis C virus treatment are unlikely to be realized, and palliative care strategies should take precedence.” Retreatment: Retreatment will be considered where there is evidence that such retreatment will improve patient outcomes. Please refer to AASLD guidelines for recommended retreatment regimens (hcvguidelines.org).
evidence exists to support initiation of hepatitis C virus treatment in patients with limited life expectancy (less than 12 months) due to comorbid conditions. For these patients, the benefits of hepatitis C virus treatment are unlikely to be realized, and palliative care strategies should take precedence.” Retreatment: Retreatment will be considered where there is evidence that such retreatment will improve patient outcomes. Please refer to AASLD guidelines for recommended retreatment regimens (hcvguidelines.org).
DRAFT%20DHCS%20hepatitis%20C%20revised%20policy%205_21_15%201100.docx